Core Viewpoint - The company demonstrates strong confidence in its business development through share buybacks and reports solid financial performance, indicating sustainable growth potential in the healthcare technology sector [1]. Financial Performance - On December 8, the company announced a share buyback of 225,000 shares at HKD 5.24 per share, totaling approximately HKD 1.18 million [1]. - The cumulative buyback over four trading days reached about 1.08 million shares, with a total expenditure exceeding HKD 5.5 million [1]. - For the fiscal year 2026 mid-term results, total revenue was RMB 358 million, reflecting an 8.7% year-on-year growth [1]. - Adjusted EBITDA for existing business was approximately RMB 54 million, doubling compared to the same period last year, nearing breakeven on the accounting level [1]. Business Development and Industry Recognition - The company, in collaboration with the Weifang Health Commission in Shandong Province, successfully applied for the "Health Portrait" and "Weifang City Universal Health Digital Portrait" projects [1]. - The company received two significant provincial awards: the "First Prize for Beneficial Service Practice" in the 2025 Shandong Province "Internet + Healthcare" Innovation Application Case and the "Service Innovation First Prize" in the inaugural "Qilu Digital Medical Health" Innovation Competition [1]. - These achievements highlight the company's role as a benchmark case for AI medical technology empowering regional health management [1].

Core Viewpoint - The company demonstrates strong confidence in its business development through share buybacks and reports solid financial performance, indicating sustainable growth potential in the healthcare technology sector [1]. Group 1: Share Buyback - On December 8, the company repurchased 225,000 shares at a price of HKD 5.24 per share, totaling approximately HKD 1.18 million [1]. - The company has conducted share buybacks for four consecutive trading days, accumulating around 1.08 million shares with a total expenditure exceeding HKD 5.5 million [1]. Group 2: Financial Performance - For the fiscal year 2026 mid-term, the company reported total revenue of RMB 358 million, reflecting a year-on-year growth of 8.7% [1]. - The adjusted EBITDA for existing operations reached approximately RMB 54 million, doubling compared to the same period last year, nearing breakeven on the accounting level [1]. - This financial milestone was achieved about one year ahead of the management's original expectations, highlighting the sustainability and growth potential of the business model [1]. Group 3: Industry Recognition - The company, in collaboration with the Weifang Health Commission in Shandong Province, successfully won two provincial awards for its "Health Portrait" and "Weifang City Universal Health Digital Portrait" projects [1]. - The awards include the "First Prize for Beneficial Service Practice" in the 2025 Shandong Province "Internet + Healthcare" Innovation Application Case and the "Service Innovation First Prize" in the inaugural "Qilu Digital Healthcare" Innovation Competition, establishing a benchmark case for AI medical technology in regional health management [1].